Abstract: Non-native synthetic peptide cyclized by means of a disulphide bridge, characterized by the amino acid sequence (E34P) that follows (SEQ ID No. 1): E-D-E-H-K-G-K-Y-C-R-L-G-N-D-C-R-T-T-E-P-T-T-T-A-T-P-R-G-T-P-T-P-A-P and a complex of non-native synthetic peptides that is intended to induce and characterize the prevention and/or treatment of conditions in mammals, the protective immunity of which depends on the stimulation of Th1 type lymphocytes, and, in particular, on a state of delayed hyperstimulation, containing: —said peptide (E34P), —the following sequence (A16E) of 16 amino acids (SEQ ID No. 2) or derivatives (structural analogues) thereof: A-A-R-C-A-R-C-R-E-G-Y-S-L-T-D-E —the following sequence (A16G) of 16 amino acids (SEQ ID No. 3) or derivatives (structural analogues) thereof: A-A-S-S-T-P-S-P-G-S-G-C-E-V-D-G, —and an adjuvant which preferably induces a cell-mediated response.
Abstract: A therapeutic vaccine peptide complex for preventing or treating disorders in mammals and particularly in humans, in Canidae, Felidae and Equidae whose protective immunity depends on the stimulation of type Th1 lymphocytes and in particular a delayed state of hypersensitivity. The vaccine peptide complex contains the following amino acid sequence (A16E): A-A-R-S-A-R-S-R-E-G-Y-S-L-T-D-E sequence wherein L can be substituted by I, and S by C, and/or the following amino acid sequence (A16G): A-A-S-S-T-P-S-P-G-S-G-C-E-V-D-G sequence wherein C can be substituted by S, and S by C, and an adjuvant which preferably induces a cell-mediated response.